Overview

Safety Study of AMG 557 in Subjects With Lupus Arthritis

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen